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Rolf Luft came to appreciate at an early stage of his career
that biomedicine, cell biology, cell physiology and genetics
arealldevelopingatatremendousrate,andthatitistherefore
of vital importance to retain a sharp focus and to address
one’s chosen research questions in great depth. For this, a lot
of hard work, talent and enthusiasm are definitely needed.
This principle guided Rolf throughout his research career
and became the golden rule for all of his pupils.
By applying his own standards Rolf was able to make a
remarkable discovery, namely that disturbed function of a
cell organelle, the mitochondrion, could lead to disease. He
later remarked that he ‘was in the position to undertake the
first studies of a cell organelle in humans in 1959–1962.
They were performed following observations made at the
bedside of a patient with striking symptoms never encoun-
tered before. The clinical observations led first to an idea
about the origin of the symptoms and second to studies of
this particular organelle, the mitochondria’ [1]. This finding
emerged from painstaking study of a 30-year-old woman
with profuse perspiration, extremely high energy intake and
myopathy [2]. He hypothesised that these abnormalities
were due to a derangement of respiratory control in the
mitochondria. The concept of oxidative phosphorylation
was at that time based on studies of rat liver mitochondria,
and he extended these techniques to mitochondria obtained
from biopsies of the patient’s gracilis muscles. The studies
showed the features of ‘loosely-coupled’ respiration, i.e.
deficient respiratory control with a partially maintained
ability to synthesise ATP. This accounted for all the clinical
features: abnormal heat production leading to increased
perspiration and the enormous energy intake needed to
compensate for the increased combustion. Electron micros-
copy of the mitochondria revealed striking structural
abnormalities, with many mitochondria of highly variable
size located in the perinuclear zone of the muscle cells and
vast paracrystalline inclusions. Despite the mystery that still
surrounds the aetiology of Luft’s disease, the demonstration
of human pathology resulting from the biochemical and
morphological abnormalities in mitochondria had a major
impact on the field of mitochondrial medicine and the
continuing growth of the field from that time.
Rolf Luft can no longer actively guide us in our daily
work. This giant in the fields of diabetes, endocrinology
and mitochondrial diseases died on 22 May 2007. Not only
will we miss his stunning intellect, but also his generosity
and humour. He was born in Stockholm on 29 June 1914.
He came from a working-class Jewish family and money
was scarce, but Rolf was a brilliant student and his studies
were funded by scholarships. He took his MD at the age of
26, and 4 years later he submitted a doctoral thesis on
Cushing’s syndrome and the effects of cortisone. He went
on to play a leading role in establishing endocrinology as a
discipline in Sweden, and also in founding the Swedish
Endocrine Society. His appointment to the Karolinska
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connected to a small research laboratory in the early 1940s.
In 1941 he showed that androgens are produced in women
by the adrenal glands. In 1946 he obtained a grant from the
Family Wallenberg Foundation and had the opportunity to
study endocrinology in the USA, with the aim of devel-
oping this discipline further in Sweden. There he demon-
strated that treatment with adrenocorticotropic hormone
(ACTH) improved the symptoms of patients with rheuma-
tism. The years 1949 to 1951 were successful ones, and
Rolf studied ‘body spaces’, ‘lean body mass’ and the
metabolic effects of hormones, especially ACTH, deoxy-
corticosterone acetate (DOCA), cortisone and growth
hormone. During the period 1951 to 1965 he introduced
hypophysectomy as a treatment for sight-threatening dia-
betic retinopathy and advanced metastatic breast cancer, on
the working hypothesis that the reduction in growth
hormone secretion could improve the outcome of these
conditions. He demonstrated that human growth hormone
has a diabetogenic effect in healthy individuals, and in
diabetic and hypophysectomised diabetic patients.
A large donation from the Family Wallenberg Founda-
tion enabled Rolf to establish the first Endocrine Clinic at
the Karolinska Institutet/Karolinska University Hospital in
Stockholm in 1958. With Errol Cerasi, he made the important
observation that an impaired first-phase insulin response to
glucose is associated with the development of type 2 diabetes.
With Suad Efendic he showed that somatostatin is produced
not onlyin the hypothalamus, but also inthe endocrine part of
the pancreas: the islets of Langerhans. Together they publish-
ed the first studies on the effects of somatostatin analogues.
Rolf Luft’s clear-sightedness made it possible to fully
establishthetranslationalconceptinmedicineattheKarolinska
Institutet/Karolinska University Hospital in Stockholm, and it
was there that he went on to establish the Rolf Luft Research
Center for Diabetes and Endocrinology, a state-of-the-art
laboratory for cell biology and molecular biology.
He started the first national programme for diabetes care
in 1967 and later founded a WHO centre for education in
diabetes. He was the president for the International
Diabetes Federation from 1973 to 1979. He was a member
of the Nobel Assembly at Karolinska Institutet (1961–
1980) and he was the president of the Nobel Committee for
Physiology or Medicine (1976–1979). Rolf was also a
member of a large number of other National and Interna-
tional organisations and associations, such as the Swedish
Royal Academy of Sciences, the Royal College of
Physicians, the National Academy of Sciences, the Amer-
ican Academy of Arts and Sciences, and the Finnish Society
of Arts and Letters. He was honourable member of most
international diabetes organisations in the world and was
awardedhonorary doctorates by many universities. Rolf Luft
received 40 international awards and medals.
Rolf also played an important role in the development of
the Swedish pharmaceutical industry. Growth hormone was
produced for the first time from pituitaries in his laboratory
in 1960, and production was later transferred to the
pharmaceutical company Kabi. In time this led to the
production of the recombinant growth hormone, Genotro-
pine, which became a leading drug for Kabi, and later for
Pharmacia.
Rolf took a great interest in and was actively involved in
social issues; in the 1960s he was instrumental in changing
the law in Sweden to recognise trans-sexuality as a medical
disorder and to permit sex changes.
Rolf Luft has played a central role for Swedish medical
research and especially the research conducted at the Karolin-
skaInstitutet.Inhishonour,theKarolinskaInstitutethas,forthe
last 6 years, given the Rolf Luft Award to world-leading
scientists for their seminal discoveries within the fields of
diabetes and endocrinology. Rolf created the Rolf Luft
Foundation for Diabetes Research in 2004.
As an expert in diabetology and endocrinology, it was
obvious to Rolf Luft that a good lifestyle is important for a
long and active life. He was a runner and a cross-country
skier and also liked to hike in the mountains. He walked
from his apartment to the Karolinska University Hospital
every day until the age of 90 years. Rolf loved to work in
the garden in his summer house outside Stockholm and
grew all sorts of vegetables there. These vegetables he
then served to his colleagues at the numerous dinners that
he hosted in his home—dinners that were full of
discussion and debate on all kinds of topics—science
and art.
Right up to his death, Rolf had an endless curiosity and
great interest in the big questions related to science and
life. He was always a most stimulating partner in
discussion and had much to offer in terms of wisdom
and good advice to his younger colleagues. It was
characteristic of Rolf that he always wanted to find out
what was going on, and even when he intellectually
understood that life must come to an end he was
emotionally unprepared. There were still papers to write,
books to read and art that should be discussed. Clearly,
Rolf did not have the time to die yet. He saw life as a
wonderful gift awarded for a very short period of time,
and that every single day should be enjoyed, something
that Rolf did. He had a long and fantastic life together
with his wonderful wife and life companion Ritva, who
was always his dearest friend and support.
Rolf has gone and we miss him enormously. However,
our joyful memories of him will make us go forward in his
698 Diabetologia (2008) 51:697–699spirit. ‘Rolf, we know that you are still keeping an eye on
us all….’
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